Ratkaistu EU-hankinta

Analgesics and anesthetics for systemic use

Finnish Institute for Health and Welfare · koko Suomi

Perustiedot

Tarjousten määräaika
ti 25.2.2025 klo 12.00 (päättynyt)
Kysymysten määräaika
ke 12.2.2025 klo 12.00 (päättynyt)
Hankkija
Finnish Institute for Health and Welfare, Y-tunnus 2229500-6
Toteutuspaikka
koko Suomi
Hankintalaji
Tavarahankinta
Menettely
Avoin menettely, EU-hankinta
Ilmoituksen tyyppi
Hankintailmoitus
Arvioitu kokonaisarvo
Ei ilmoitettu
Erät
5 erää
Pääasiallinen CPV
33661000 Hermostoon vaikuttavat lääkkeet
Lisäkoodit: 33600000
Sopimuskausi
16 kuukautta
Julkaistu
23.1.2025

Ilmoituksen teksti

Alkuperäinen teksti Hilmasta, muuttamattomana
Finnish Institute for Health and Welfare, later referred to as THL or Customer, request your tender for "Analgesics and anesthetics for systemic use" to the rescEU Medical -project. The Scope of procurement is described in more detail in Annex 1. The procurement is divided in five (5) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots. LOT 1: Fentanyl citrate 50 mcg/ml (10 ml per vial/ampoule, i.v. ATC N01AH01) LOT 2: Haloperidol 5 mg/ml (1 ml per vial/ampoule, i.m. ATC N05AD01) LOT 3: Midazolam hydrochlorid 5 mg/ml (10 ml per vial/ampoule, i.v. ATC N05CD08) LOT 4: Glycopyrrhonium/neostigmin 0,5/2,5 mg/ml (1 ml per vial/ampoule i.v. ATC N07AA51) LOT 5: Oxycodon hydrochlorid 20 mg (prolonged-release capsule/tablet, ATC N02AA05) The minimum requirements for the products is described in Annex 1.1. The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The contract period shall enter into force once the Contract has been signed by contracting parties and expires when all contractual duties of the Contract have been performed. Quantity for the products is described in Annex 7 (restricted to security classification level IV, TL IV). In addition to the quantity indicated in the Annex 7, the Customer is entitled to purchase 100 % extra to the quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option. Please note that all times given in the Call for tenders refer to local time in Finland. Call for tenders, Annexes: Annex 1 Scope of the procurement Annex 1.1 Minimum requirements Annex 2 Description of the rotation Annex 2.1 Quality scoring table Annex 3 Contract Annex 4 Security annex Annex 5 JYSE 2014 SUPPLIES (updated version of April 2022) Annex 6 Confidentiality commitment Annex 7 Quantity of the Articles (restricted, TL IV) Please note that the numbering of the annexes differs between the Contract and the Call for tenders. The numbering of the Annexes to the Contract is based on the order of precedence applied in the Contract.

Lisätiedot

The availability for the Annex 7 is restricted to security classification level IV (TL IV). THL will send the Annex 7 to a representative of the tenderer via encrypted email after THL has received a scanned version of the signed Confidentiality commitment (Annex 6). The signature of the Confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/7274/2.02.06/2024 / Analgesics and anesthetics for systemic use". The message shall contain name of the tenderer and email address to which the Annex 7 is to be sent.

Erien kuvaukset

Erä 1: LOT 1: Fentanyl citrate 50 mcg/ml (10 ml per vial/ampoule, i.v. ATC N01AH01)
The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Fentanyl citrate 50 mcg/ml (10 ml per vial/ampoule, i.v. ATC N01AH01) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Fentanyl citrate - Strength: 50 mcg/ml - Pharmaceutical form: 10 ml i.v., per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 2: LOT 2: Haloperidol 5 mg/ml (1 ml per vial/ampoule, i.m. ATC N05AD01)
The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Haloperidol 5 mg/ml (1 ml per vial/ampoule, i.m. ATC N05AD01) - Parenteral products (intramuscular administration) - Active pharmaceutical ingredient: Haloperidol - Strength: 5 mg/ml - Pharmaceutical form: 1 ml i.m., per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.

Lisätiedot

The availability for the Annex 7 is restricted to security classification level IV (TL IV). THL will send the Annex 7 to a representative of the tenderer via encrypted email after THL has received a scanned version of the signed Confidentiality commitment (Annex 6). The signature of the Confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/7274/2.02.06/2024 / Analgesics and anesthetics for systemic use". The message shall contain name of the tenderer and email address to which the Annex 7 is to be sent.
Erä 3: LOT 3: Midazolam hydrochlorid 5 mg/ml (10 ml per vial/ampoule, i.v. ATC N05CD08)
The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Midazolam hydrochlorid 5 mg/ml (10 ml per vial/ampoule, i.v. ATC N05CD08) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Midazolam hydrochlorid - Strength: 5 mg/ml - Pharmaceutical form: 10 ml i.v., per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 4: LOT 4: Glycopyrrhonium/neostigmin 0,5/2,5 mg/ml (1 ml per vial/ampoule i.v. ATC N07AA51)
The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Glycopyrrhonium/neostigmin 0,5/2,5 mg/ml (1 ml per vial/ampoule i.v. ATC N07AA51) - Parenteral products (intravenous administration) - Active pharmaceutical ingredient: Glycopyrrhonium/neostigmin - Strength: 0,5/2,5 mg/ml - Pharmaceutical form: 1 ml i.v., per vial/ampoule The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.

Lisätiedot

The availability for the Annex 7 is restricted to security classification level IV (TL IV). THL will send the Annex 7 to a representative of the tenderer via encrypted email after THL has received a scanned version of the signed Confidentiality commitment (Annex 6). The signature of the Confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/7274/2.02.06/2024 Analgesics and anesthetics for systemic use". The message shall contain name of the tenderer and email address to which the Annex 7 is to be sent.
Erä 5: LOT 5: Oxycodon hydrochlorid 20 mg (prolonged-release capsule/tablet, ATC N02AA05)
The subject of the procurement is Article in accordance with the following requirements: - The subject of tender: Oxycodon hydrochlorid 20 mg (prolonged-release capsule/tablet, ATC N02AA05) - Oral solid dosage forms - Active pharmaceutical ingredient: Oxycodon hydrochlorid - Strength: 20 mg - Pharmaceutical form: prolonged-release capsule/tablet The minimum requirements of the Article is described in more detail in Annex 1.1. The delivery schedule for the articles is described in Annex 1. Quantity for the Article is described in Annex 7 (restricted, TL IV). In addition to the quantity of the Articles indicated in the Annex 7, the Customer shall be entitled to purchase 100 % extra to the original quantities (later referred as "Option") described in the Annex 7. The decision to exercise the Option is in the Customer´s sole discretion. Customer should exercise the Option in part or in whole. The Customer shall notify the Supplier at the latest by the end of June 2026 if it wishes to take on the Option. The delivery schedule for the Option shall be agreed separately between the Contracting Parties. Nevertheless, the Supplier shall not be obliged to agree to deliver the Option to the Customer. The tender shall consist of one (1) Article. The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.

Lisätiedot

The availability for the Annex 7 is restricted to security classification level IV (TL IV). THL will send the Annex 7 to a representative of the tenderer via encrypted email after THL has received a scanned version of the signed Confidentiality commitment (Annex 6). The signature of the Confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the email address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/7274/2.02.06/2024 Analgesics and anesthetics for systemic use". The message shall contain name of the tenderer and email address to which the Annex 7 is to be sent.

Erät

Erä Nimi Ammattiala Arvioitu arvo CPV
1 LOT 1: Fentanyl citrate 50 mcg/ml (10 ml per vial/ampoule, i.v. ATC N01AH01) Ratkaistu – – 33661100
2 LOT 2: Haloperidol 5 mg/ml (1 ml per vial/ampoule, i.m. ATC N05AD01) Keskeytetty – – 33661500
3 LOT 3: Midazolam hydrochlorid 5 mg/ml (10 ml per vial/ampoule, i.v. ATC N05CD08) Ratkaistu – – 33661500
4 LOT 4: Glycopyrrhonium/neostigmin 0,5/2,5 mg/ml (1 ml per vial/ampoule i.v. ATC N07AA51) Ratkaistu – – 33661700
5 LOT 5: Oxycodon hydrochlorid 20 mg (prolonged-release capsule/tablet, ATC N02AA05) Keskeytetty – – 33661200

Hankinnan vaiheet

  1. Hankintailmoitustämä ilmoitus

    Tarjouspyyntö julkaistiin, määräaika 25.2.2025 klo 12.00.

  2. Jälki-ilmoitus

    Voittajat: Grindeks Kalceks Suomi Oy ja EQL Pharma AB.

Lähde: Hilma (hankintailmoitukset.fi)

Ilmoitus 2025-019491

Ilmoita virheestä tai pyydä poistoa